Consistent with the reversibility of persister states observed in other cancer cell models, the removal of lapatinib for two weeks allowed OE19-PS cells to re-acquire sensitivity to HER2 blockade (Fig. 1A, B) [25]. The gene discussed is ERBB2; the disease is cancer.